Fri, Aug 22, 2014, 5:02 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

GTX Corp Message Board

walktheline43 23 posts  |  Last Activity: Aug 16, 2014 12:12 PM Member since: Jun 3, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • walktheline43 walktheline43 Aug 16, 2014 12:12 PM Flag

    Someone painted the tape. Look at the trades yesterday. All accumilation until the last 3 prints on 700, 200 and 200 share trades everything before was $9 or high $8's. Usually you see this when equity is going to be issued and price is based on average closing price. There is no equity being issued here so I think it's MM's keeping it artificially low for now.

    Sentiment: Strong Buy

  • Reply to

    You all read the SA article...

    by ndanger2 Aug 8, 2014 5:30 PM
    walktheline43 walktheline43 Aug 15, 2014 3:51 PM Flag

    Some nice large buys today.

    Sentiment: Strong Buy

  • Reply to

    You all read the SA article...

    by ndanger2 Aug 8, 2014 5:30 PM
    walktheline43 walktheline43 Aug 9, 2014 10:31 PM Flag

    I don't think that the seeking alpha article drove the volume . It didn't provide anything new that any long already knows. SA articles for the most part can not be trusted as they typically are spun by an investor or group of investors to manipulate the price. I think that the recent uptick is mostly being driven by the market makers to align inventory of shares. That is why the price didn't jump on a 5 year high of volume.

    That being said I see this as an extremely positive thing. Don't get me wrong there are new investors coming in. Small blocks but bullish none the less. Dog data is key right now. Other than a possible new investor coming in on the smoking cessation spin off or finally a long awaited road show to bring in new fund managers I don't think there is anything else to motivate a price increase . Current market conditions and a pumped up bio sector that has been selling off don't help but we are holding up well.

    Strong hands and limited shares are rocket fuel when we receive the positive dog data (fingers crossed). I continue to add shares whenever I can. This is a very exciting opportunity for us and I have not been so optimistic in an investment as I am with ARDM. Management is doing a fantastic job getting all the ducks in a row. They are clearly sincere in their claim to look out for the best interest of us small investors. Keep up the great work.

    Sentiment: Strong Buy

  • Reply to

    9 month dog study is done...

    by ndanger2 Aug 6, 2014 10:27 PM
    walktheline43 walktheline43 Aug 7, 2014 8:43 AM Flag

    we can only hope ndanger2. But I agree with you. It hasn't been much but volume has picked up a little bit.

    Sentiment: Strong Buy

  • Reply to

    lifesci advisors PR on ARDM

    by walktheline43 Jun 30, 2014 12:33 PM
    walktheline43 walktheline43 Jun 30, 2014 1:26 PM Flag

    Aradigm’s Development Programs Compare Favorably to Insmed’s Arikayce. Insmed is another potential competitor in this space that has also developed a liposomally-packaged antibiotic for inhalation to treat chronic lung infections. Insmed’s lead candidate, Arikayce, has been tested in clinical trials to treat lung infections from Pseudomonas aeruginosa in cystic fibrosis and non-CF BE, as well as nontuberculous mycobacteria (NTM) infections. Although this largely overlaps with the indications for Pulmaquin and Lipoquin, the companies have prioritized these indications differently. Insmed has focused on development and has completed a Phase III trial for the CF indication, while Aradigm is focusing on non-CF BE.
    In Phase II trials for the non-CF BE indication, Insmed found only a small change in CFU of Pseudomonas aeruginosa compared to Aradigm’s Phase II Pulmaquin findings. In addition, although there were no major safety issues, the high-dose group experienced a slight deterioration of lung function as measured by the forced expiratory volume (FEV) with spirometry. Due to lung sensitivity in BE patients, a treatment isn’t necessarily expected to improve the lungs, but when it produces worsening lung functions it is unlikely to gain regulatory approval. This is likely a reason that Insmed has not aggressively pursued this indication to date, leaving only Aradigm’s development program to address this significant unmet need for BE patients with an inhaled liposomal antibiotic formulation. Bayer corporation is testing a non-liposomal, dry powder formulation of ciprofloxacin in these patients; based on data collected to date, the anti-pseudomonal activity of Bayer’s product appears to be significantly lower than that of Pulmaquin.

    Sentiment: Strong Buy

  • walktheline43 by walktheline43 Jun 30, 2014 12:33 PM Flag

    I just received a PR from lifesci advisors that has done an initiation of coverage paper/write up on ARDM. google the website it should be on the front page right side. nice to see some more interest in our hidden gem.

    Sentiment: Strong Buy

  • Reply to

    Volume Spike

    by palmoscopy Jun 17, 2014 4:10 PM
    walktheline43 walktheline43 Jun 19, 2014 4:04 PM Flag

    Games on the prints....slow accumulation....

    15:59:49 9.00 25 NSD
    15:59:49 9.00 100 ARCA
    15:59:49 9.00 75 ARCA
    15:59:49 9.01 100 NSD
    15:59:49 9.00 100 NSD
    15:59:49 9.00 100 NSD
    15:59:49 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:44 9.00 100 NSD
    15:59:41 9.00 100 NSD
    15:59:41 9.00 100 NSD
    15:59:41 9.00 200 NSD
    15:59:41 9.00 100 NSD
    15:59:41 9.00 200 NSD
    15:59:41 9.00 100 NSD
    15:59:41 9.00 200 NSD
    15:59:31 9.00 100 NSD
    15:59:31 9.00 100 NSD

    Sentiment: Strong Buy

  • walktheline43 by walktheline43 Jun 19, 2014 8:25 AM Flag

    But why we patiently wait for ARDM to go up has anyone been watching INSM? After the recent pull back yesterday's news catapulted it.

    "The share price surged after the Food and Drug Administration granted Arikayce, its lead investigational drug, breakthrough therapy designation".

    it's amazing how explosive these drug stocks can be.

    Sentiment: Strong Buy

  • Reply to

    Volume Spike

    by palmoscopy Jun 17, 2014 4:10 PM
    walktheline43 walktheline43 Jun 17, 2014 7:43 PM Flag

    Going in the right direction but we need to start seeing 50k, then 100k and then multiple days of vol. I was watching today a little and kept seeing lots of 100 going off at the bid with no move on the bid or ask. Perhaps some shares starting to trade hands behind the scene? No volume so hard to speculate. I expect a move to take it down but with no inventory that may be tough unless a strong hand dumps some.

    Sentiment: Strong Buy

  • Reply to

    Steep drop

    by la.taupe Jun 12, 2014 10:14 AM
    walktheline43 walktheline43 Jun 13, 2014 7:39 AM Flag

    la, I think that one of the key triggers will be coverage from the Investment Banks/funds. Before they do that they are going to want to take positions. But before they take positions they need to buy into the dream. So, its sort of a marketing game right now. Management must get the Company and a better understanding of the pipeline out there. Now that we have the Q status more people will be listening at conferences and on management calls. I am sure that ARDM management is also scheduling meetings with these fund managers as well.

    Seeing the bid and ask getting more in line is a good sign. I think that the MM's are still probably trying to balance the books and understand what the share inventory looks like. For the funds to buy in they will want to do so in decent blocks at a set price. Once we start seeing volume and big blocks coverage and future price predictions will be around the corner. Not to discount Penny Stock Weekly as I see they have recently claimed a no brainer double but we have graduated from that stock index. time for bigger and better! Stay strong good times are coming.

    Sentiment: Strong Buy

  • Reply to

    Up 35% Currently

    by palmoscopy Jun 9, 2014 10:20 AM
    walktheline43 walktheline43 Jun 9, 2014 10:22 AM Flag

    MM's are scrambling...inventory is scarce. If they have been shorting they could be in trouble...

    Sentiment: Strong Buy

  • Reply to

    ARDM To NASDAQ

    by rossphi Jun 9, 2014 7:19 AM
    walktheline43 walktheline43 Jun 9, 2014 8:37 AM Flag

    Excellent! Nice to see that they had everything lined up and timed with the reverse. Very professional in my opinion. Let's get this train rolling! Hopefully they have a few key PR's line up as well.

    Sentiment: Strong Buy

  • Reply to

    I just added 250 shares

    by vinnie_baggadonitz Jun 6, 2014 12:13 PM
    walktheline43 walktheline43 Jun 6, 2014 4:55 PM Flag

    Well when it hits $35 per share it will seem like a lot more!

    Sentiment: Strong Buy

  • Reply to

    Importance of first Phase III patient

    by rehdvm2004 Jun 3, 2014 8:47 AM
    walktheline43 walktheline43 Jun 3, 2014 7:02 PM Flag

    Reh, does this mean that the phase 3 trials could have a various secondary or further end points based on FEV1? If so is there any type of standard that we should be looking for? Appears that FHV would be based on the delivery method which seems like we have a proven one. Can you expand on this? Thanks

    Sentiment: Strong Buy

  • walktheline43 walktheline43 Jun 3, 2014 7:39 AM Flag

    well there you go...ask and you shall receive. $5 million payment in hand. I am not sure on the Q timing. I had asked that question on the other board and have not received a response. I guess I will need to do some research.

    Sentiment: Strong Buy

  • Reply to

    Temporarily in the penalty box...

    by ndanger2 May 30, 2014 1:41 PM
    walktheline43 walktheline43 May 31, 2014 11:36 AM Flag

    By my count it's only 3 million in the float.

    Sentiment: Strong Buy

  • Reply to

    No interest !!

    by wpostm May 30, 2014 11:03 AM
    walktheline43 walktheline43 May 31, 2014 7:32 AM Flag

    Once they file and get approved for Q status I imagine that things will change. There is only 3 million shares in the float and I wouldn't be surprised if a million of those are in tight hands. It won't take much to launch this. Just wait a little longer.

    Sentiment: Strong Buy

  • Reply to

    ARDM is dead to me.

    by slope661 May 27, 2014 8:39 PM
    walktheline43 walktheline43 May 28, 2014 2:40 PM Flag

    How long does a stock that has done a reverse split keep the letter "D" at the end of its symbol?


    By Casey Murphy on February 26, 2009

    A A A

    Filed Under: Day Trading, Stock Market Terminology, Technical Analysis


    A reverse split is a corporate action whereby a company reduces the number of shares outstanding and increases the price of its stock. A company may decide to use a reverse split to shed its status as a penny stock, or to avoid being delisted. A common type of reverse stock split is 1:2, which means that each investor receives one share for every two that he or she already holds. In other words, the investor gets half as many shares, but they're worth twice as much as before.

    As the question states, a company that has undergone a reverse stock split often gets the letter "D" attached to the end of its ticker symbol. This letter is used to designate a company that is undergoing a stock split of some sort (most often a reverse split), or some form of corporate reorganization. This letter is generally attached to the end of the ticker for approximately 20 trading days before it's removed.

    Sentiment: Strong Buy

  • Reply to

    ARDM is dead to me.

    by slope661 May 27, 2014 8:39 PM
    walktheline43 walktheline43 May 28, 2014 8:05 AM Flag

    you have about 18 more days to enjoy the D before it goes back to sans D.

  • walktheline43 walktheline43 May 27, 2014 6:38 PM Flag

    Agreed RS's stink. Usually they correlate with new equity being issued. That is the killer for the longs. Don't see that happening here but if it did that would surely be a big #$%$ to all of us by management. Instead I would like to see an opportunity for cheap shares as we get through this "D" process, apply for the "Q" so that we can all make some "$".

    Sentiment: Strong Buy

GTXO
0.012-0.002(-13.04%)Aug 22 3:29 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.